Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 19Lymphoma, Non-Hodgkin 11Hodgkin Disease 10Leukemia, Biphenotypic, Acute 8Multiple Myeloma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia 7Burkitt Lymphoma 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Neuroblastoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Anemia, Refractory, with Excess of Blasts 5Recurrence 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Breast Neoplasms 4Lymphoma, T-Cell 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Sarcoma 2Rhabdomyosarcoma 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Myelodysplastic-Myeloproliferative Diseases 2Medulloblastoma 2

Interventions

pembrolizumab 3Paclitaxel 3Doxorubicin 3durvalumab 2Standard of Care 2Nivolumab 2Ipilimumab 2Ifosfamide 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1sarilumab 1regorafenib 1pexidartinib 1pertuzumab 1peginterferon alfa-2a 1pazopanib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × Granulocyte Colony-Stimulating Factor × 1 year × Clear all
NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡